SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal diseases, at the Crohn's & Colitis Congress® in Las Vegas, NV.
Presentation Details:
Title:
Olorinab, a Peripherally Restricted, Highly Selective Agonist of
the Cannabinoid Receptor Type 2 for the Management of Visceral Pain
in Inflammatory Bowel Disease (IBD)âPreclinical and Early Clinical
Development
Poster Presentation
Dates: Thursday, Feb. 7, 7:15PM
PST and Friday, Feb. 8, 3:50PM
PST
About Olorinab
Olorinab (APD371) is
an oral, peripherally restricted, highly selective, full agonist of
cannabinoid receptor type 2 (CB2) in development for the
treatment of visceral pain associated with gastrointestinal (GI)
diseases, including Crohn's disease and irritable bowel syndrome
(IBS). Evidence that CB2 are expressed in multiple
cell types of the GI tract, and modulate intestinal inflammation
and visceral hypersensitivity, make CB2 an attractive
target for the treatment of abdominal pain in GI disorders.
Olorinab is an investigational compound that is not approved for any use in any country.
About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to
deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune and inflammatory conditions, is
being evaluated in later-stage clinical programs in ulcerative
colitis (UC) and Crohn's disease, as well as in programs for other
indications such as atopic dermatitis. Arena is also evaluating
olorinab (APD371) in a Phase 2 program
for gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including
APD418 for decompensated heart failure.
Arena's licensee, United Therapeutics, is evaluating ralinepag
(APD811) in a Phase 3 program for pulmonary arterial hypertension
(PAH).
Arena has additional license agreements and partnerships, including with Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target â preclinical), Outpost Medicine, LLC (undisclosed target â preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® â marketed product).
Forward-Looking Statements
Certain
statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. These
forward-looking statements may be accompanied by words such as
"will," "in development for," "driven to," "potentially,"
"potential," or words of similar meaning, or they may be identified
by the fact that they do not relate strictly to historical or
current facts. Such forward-looking statements include, without
limitation, statements about the following: the opportunity,
development and potential of olorinab and Arena's other
investigational drug candidates, including to be first- or
best-in-class, have broad clinical utility, or have utility in a
broad range of immune and inflammatory conditions; Arena's
drive; and the potential of Arena's assets, programs, licenses, and
collaborations. For such statements, Arena claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include: the timing and outcome of
research, development and regulatory review is uncertain; results
of clinical trials and other studies are subject to different
interpretations and may not be predictive of future results;
nonclinical and clinical data are voluminous and detailed, and
regulatory agencies may interpret or weigh the importance of data
differently and reach different conclusions than Arena or others,
request additional information, have additional recommendations or
change their guidance or requirements before or after approval; we
expect to need additional funds to advance all of our programs, and
you and others may not agree with the manner we allocate our
resources; clinical trials and other studies may not proceed at the
time or in the manner expected or at all; enrolling patients in our
ongoing and intended clinical trials is competitive and
challenging; our drug candidates may not advance in development or
be approved for marketing; unexpected or unfavorable new data;
risks related to developing and commercializing drugs; risks
related to relying on partners and other third parties; Arena's and
third parties' intellectual property rights; and satisfactory
resolution of litigation or other disagreements with others.
Additional factors that could cause actual results to differ
materially from those stated or implied by Arena's forward-looking
statements are disclosed in Arena's filings with the Securities and
Exchange Commission (SEC), including but not limited to our
Quarterly Report on Form 10-Q for the quarter ended September
30, 2018, which was filed with the SEC on November 8,
2018. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
[email protected]
858.210.3636
Media Contact:
Matt Middleman,
MD
LifeSci Public Relations
[email protected]
646.627.8384
View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presents-preclinical-and-early-clinical-development-data-for-olorinab-at-crohns--colitis-congress-300792077.html